Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Kits Eyecare Ltd T.KITS

Alternate Symbol(s):  KTYCF

Kits Eyecare Ltd. is a Canada-based provider of vertically integrated and digitally native eyecare platforms. The Company operates through the sale of eyewear products to consumers. It offers customers access to a selection of contact lenses and eyeglasses, including its own KITS-designed products, as well as an advanced suite of online vision tools. Its collections include South Beach, Little Italy, Trail Blazer, KITS x Vasuma and Apres. The Company's designer glasses and sunglasses, including Alexander Mcqueen, Armourx, Betsey Johnson, Bottega Veneta, Calvin Klein Carrera, David Beckham, Diesel, Dior, Emilio Pucci, Emporio Armani, Gucci, Hugo Boss, Jimmy Choo, Judith Leiber, Kits, Persol, Prada, Ray-Ban, Superdry, Tom Ford, Under Armour, And Versace.


TSX:KITS - Post by User

Post by nozzpackon Aug 16, 2022 9:51pm
119 Views
Post# 34901041

Multiples of Upside Upon Recognition of Value

Multiples of Upside Upon Recognition of Value

"While there are no perfect public comparable companies to Kits Eyecare, we believe the broader eye wear retail peer set is an appropriate barometer, with the group trading at an average of 3.8 times 2022 sales. 


In our view, Kits Eyecare should trade at a premium to these peers, given its earlier stage in the growth cycle, higher expected revenue growth, healthy balance sheet, and strong management team."

Kits is on track for $95 million in Revenue this year, with rapidly increasing recurring sales which are higher margin.

At 3.8 times 2022 revenue of $95 million, fair peer based market cap would be about $350 million which equates to about $11+ dollars per share.

$19 million in cash and now cash flow positive with margins creeping up to very robust levels.

A great disruptive model as well.

In fact, buying your eyeglasses and contacts online is easy , cheaper and very convenient, as I found out.

I am now a proud customer..

<< Previous
Bullboard Posts
Next >>